Case Study: Compassionate use of remdesivir of Gilead for COVID-19

During an extraordinary virtual meeting held on April 2, 2020, EMA’s human medicines committee (CHMP) gave recommendations on how the investigational antiviral medicine remdesivir should be used for treating coronavirus disease (COVID-19) in compassionate use programmes in the European Union. What is Compassionate use programmes? Compassionate use programmes, which are set up at the level … Continue reading Case Study: Compassionate use of remdesivir of Gilead for COVID-19